Compare ELTX & VTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | VTSI |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 51.0M |
| IPO Year | 2014 | 1999 |
| Metric | ELTX | VTSI |
|---|---|---|
| Price | $2.18 | $2.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $18.00 | $5.00 |
| AVG Volume (30 Days) | ★ 266.2K | 33.8K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,301,000.00 | $185,971.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $27.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.34 | $2.88 |
| 52 Week High | $16.00 | $6.29 |
| Indicator | ELTX | VTSI |
|---|---|---|
| Relative Strength Index (RSI) | 24.01 | 41.98 |
| Support Level | N/A | N/A |
| Resistance Level | $3.32 | $3.59 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 1.09 | 7.92 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.